No Data
No Data
BeiGene, Ltd. (NASDAQ:BGNE) Surges 27% Yet Its Low P/S Is No Reason For Excitement
Top Gap Ups and Downs on Friday: SONY, IBN, DEO and More
Jefferies Maintains BeiGene(BGNE.US) With Buy Rating, Raises Target Price to $284
Jefferies Sticks to Their Buy Rating for BeiGene (BGNE)
Monkeypox epidemic is fermenting! Biomedical stocks on the Hong Kong stock market continue to be active. Institutions are expected to see a concentrated bullish catalyst.
Which mid-term bullish trends are worth paying attention to in the continuously active Hong Kong biomedical sector? What are the highlights of the Wande Innovative Drugs Index outperforming the market since July?
BeiGene Announces New Stock Incentives
No Data